Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry
Year: 2024
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: We assessed the prognostic utility of circulating levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry. METHODS: MMP and TIMP concentrations were quantified by ELISA in plasma from 300 patients. A Cox proportional hazard regression model was used to assess associations between select MMPs and TIMPs and death and disease progression (absolute decline in forced vital capacity ≥10% predicted, death, or lung transplant). RESULTS: Over a median follow-up of 30.4 months, 98 patients died and 182 patients had disease progression. In unadjusted analyses, higher concentrations of MMPs 2, 3, 8 and 9 and TIMPs 1, 2 and 4 were associated with an increased risk of death. MMPs 2 and 8 and TIMP1 remained associated with death after adjustment for clinical factors. In unadjusted analyses, higher concentrations of MMPs 8 and 9 and TIMPs 1 and 4 were associated with an increased risk of disease progression. MMPs 8 and 9 and TIMP1 remained associated with progression after adjustment for clinical factors. CONCLUSION: Circulating levels of MMP8 and TIMP1 may provide information on the risk of outcomes in patients with IPF not captured by clinical measures.
Source: PLoS ONE
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,290
Funders: Yale University, Vanderbilt University, University of Miami, University of Pennsylvania, Wake Forest University, University of Minnesota, Cleveland Clinic, Baylor University, Tulane University, University of Texas Southwestern Medical Center, University of Pittsburgh, University of Louisville, University of Cincinnati, Boehringer Ingelheim, University of South Carolina, Medical College of Wisconsin, Temple University, National Jewish Health, Vanderbilt University Medical Center, University of California, Los Angeles, Weill Cornell Medical College, University of California, Davis, Baylor University Medical Center, Houston Methodist Research Institute, Duke Clinical Research Institute
OpenAlex ID: W4403513465